Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Gastroenterology Unit, Azienda Ospedaliero-Universitaria di Cagliari,Italy.
IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini, Rome, Italy; Department of Gastroenterology and Digestive Endoscopy, San Raffaele Hospital and Vita-Salute San Raffaele Hospital, Milan, Italy.
J Crohns Colitis. 2024 Aug 14;18(8):1222-1231. doi: 10.1093/ecco-jcc/jjae026.
Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was developed to identify essential criteria and address key methodological issues needed to design valid, comparative, pragmatic studies in inflammatory bowel diseases [BDs].
Statements were issued by a panel of 11 European experts in IBD management and trial methodology, on four main topics: [I] study design; [II] eligibility, recruitment and organisation, flexibility; [III] outcomes; [IV] analysis. The consensus process followed a modified Delphi approach, involving two rounds of assessment and rating of the level of agreement [1 to 9; cut-off ≥7 for approval] with the statements by 18 additional European experts in IBD.
At the first voting round, 25 out of the 26 statements reached a mean score ≥7. Following the discussion that preceded the second round of voting, it was decided to eliminate two statements and to split one into two. At the second voting round, 25 final statements were approved: seven for study design; six for eligibility, recruitment and organisation, flexibility; eight for outcomes; and four for analysis.
Pragmatic, randomised, clinical trials can address important questions in IBD clinical practice, and may provide complementary, high-level evidence, as long as they follow a methodologically rigorous approach. These 25 statements intend to offer practical guidance in the design of high-quality, pragmatic, clinical trials that can aid decision making in choosing a management strategy for IBDs.
旨在检验日常临床环境下干预措施的实用性研究,可以成功补充注册和解释性临床试验的证据。欧洲共识项目 PRACTICE-IBD 旨在确定设计有效的、具有可比性的、实用性炎症性肠病(IBD)研究所需的基本标准和解决关键方法学问题。
IBD 管理和试验方法学的 11 位欧洲专家小组就四个主要主题发布了声明:[I]研究设计;[II]合格性、招募和组织、灵活性;[III]结局;[IV]分析。共识过程遵循改良 Delphi 方法,包括两轮评估和对 18 位额外的 IBD 欧洲专家对声明的一致性程度(1 到 9;≥7 为批准)进行评分。
在第一轮投票中,26 项声明中有 25 项得分为≥7。在第二轮投票前的讨论之后,决定删除两项声明,并将一项声明分为两项。在第二轮投票中,批准了 25 项最终声明:7 项用于研究设计;6 项用于合格性、招募和组织、灵活性;8 项用于结局;4 项用于分析。
实用性、随机对照临床试验可以解决 IBD 临床实践中的重要问题,并可以提供补充性的高水平证据,只要它们遵循严格的方法学方法。这 25 项声明旨在为高质量、实用性临床试验的设计提供实用指导,以帮助在选择 IBD 管理策略时做出决策。